Abstract
Advances in the field of epigenetics have allowed the design of new therapeutic strategies to address complex diseases such as type 1 diabetes (T1D). Clustered regularly interspaced short palindromic repeats (CRISPR)-on is a novel and powerful RNA-guided transcriptional activator system that can turn on specific gene expression; however, it remains unclear whether this system can be widely used or whether its use will be restricted depending on cell types, methylation promoter statuses or the capacity to modulate chromatin state. Our results revealed that the CRISPR-on system fused with transcriptional activators (dCas9-VP160) activated endogenous human INS, which is a silenced gene with a fully methylated promoter. Similarly, we observed a synergistic effect on gene activation when multiple single guide RNAs were used, and the transcriptional activation was maintained until day 21. Regarding the epigenetic profile, the targeted promoter gene did not exhibit alteration in its methylation status but rather exhibited altered levels of H3K9ac following treatment. Importantly, we showed that dCas9-VP160 acts on patients’ cells in vitro, particularly the fibroblasts of patients with T1D.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Progress and Challenges
Stem Cell Reviews and Reports Open Access 03 September 2020
-
Delivery systems of CRISPR/Cas9-based cancer gene therapy
Journal of Biological Engineering Open Access 18 December 2018
-
CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?
Stem Cell Research & Therapy Open Access 09 March 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout




References
Togliatto G, Dentelli P, Brizzi MF . Skewed epigenetics: an alternative therapeutic option for diabetes complications. J Diabetes Res 2015; 2015: 373708.
de Groote ML, Verschure PJ, Rots MG . Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res 2012; 40: 10596–10613.
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816–821.
Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE et al. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823–826.
Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013; 152: 1173–1183.
Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 2014; 159: 647–661.
Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK . CRISPR RNA-guided activation of endogenous human genes. Nat Methods 2013; 10: 977–979.
Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 2013; 10: 973–976.
Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW et al. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res 2013; 10: 1163–1171.
Chakraborty S, Ji H, Kabadi AM, Gersbach CA, Christoforou N, Leong KW . A CRISPR/Cas9-based system for reprogramming cell lineage specification. Stem Cell Rep 2014; 3: 940–947.
Copeland MF, Politz MC, Pfleger BF . Application of TALEs, CRISPR/Cas and sRNAs as trans-acting regulators in prokaryotes. Curr Opin Biotechnol 2014; 29: 46–54.
Gersbach CA, Perez-Pinera P . Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine. Expert Opin Ther Targets 2014; 8: 835–839.
Balboa D, Weltner J, Eurola S, Trokovic R, Wartiovaara K, Otonkoski T . Conditionally stabilized dCas9 activator for controlling gene expression in human cell reprogramming and differentiation. Stem Cell Rep 2015; 5: 448–459.
Hu J, Lei Y, Wong WK, Liu S, Lee KC, He X et al. Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors. Nucleic Acids Res 2014; 7: 4375–4390.
Liu J, Jia G . Methylation modifications in eukaryotic messenger RNA. J Genet Genomics 2014; 41: 21–33.
Lee EK, Gorospe M . Minireview: posttranscriptional regulation of the insulin and insulin-like growth factor systems. Endocrinology 2010; 151: 1403–1408.
Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013; 31: 827–832.
Agalioti T, Chen G, Thanos D . Deciphering the transcriptional histone acetylation code for a human gene. Cell 2002; 111: 381–392.
Ikeda K, Stuehler T, Meisterernst M . The H1 and H2 regions of the activation domain of herpes simplex virion protein 16 stimulate transcription through distinct molecular mechanisms. Genes Cells 2002; 1: 49–58.
Tie F, Banerjee R, Stratton CA, Prasad-Sinha J, Stepanik V, Zlobin A et al. CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing. Development 2009; 18: 3131–3141.
Yuan H, Reddy MA, Sun G, Lanting L, Wang M, Kato M et al. Involvement of p300/CBP and epigenetic histone acetylation in TGF-β1-mediated gene transcription in mesangial cells. Am J Physiol Renal Physiol 2013; 304: F601–F613.
Wang T, Liu H, Ning Y, Xu Q . The histone acetyltransferase p300 regulates the expression of pluripotency factors and odontogenic differentiation of human dental pulp cells. PLoS ONE 2014; 9: e102117.
Puri S, Folias AE, Hebrok M . Plasticity and dedifferentiation within the pancreas: development, homeostasis, and disease. Cell Stem Cell 2015; 16: 18–31.
Pereyra-Bonnet F, Gimeno ML, Argumedo NR, Ielpi M, Cardozo JA, Giménez CA et al. Skin fibroblasts from patients with type 1 diabetes (T1D) can be chemically transdifferentiated into insulin-expressing clusters: a transgene-free approach. PLoS ONE 2014; 9: e100369.
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F . Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013; 8: 2281–2308.
Haring M, Offermann S, Danker T, Horst I, Peterhansel C, Stam M . Chromatin immunoprecipitation: optimization, quantitative analysis and data normalization. Plant Methods 2007; 3: 11.
Jiang M, Zhang Y, Fei J, Chang X, Fan W, Qian X et al. Rapid quantification of DNA methylation by measuring relative peak heights in direct bisulfite-PCR sequencing traces. Lab Invest 2010; 90: 282–290.
Matarazzo MR, Lembo F, Angrisano T, Ballestar E, Ferraro M, Pero R et al. In vivo analysis of DNA methylation patterns recognized by specific proteins: coupling CHIP and bisulfite analysis. Biotechniques 2004; 37: 666–668; 670, 672–673.
Fradin D, Le Fur S, Mille C, Naoui N, Groves C, Zelenika D et al. Association of the CpG methylation pattern of the proximal insulin gene promoter with type 1 diabetes. PLoS ONE 2012; 7: e36278.
Acknowledgements
This work is dedicated to the memory of Dr Pablo Argibay. CG and FPB were financed by CONICET. We thank Dr Masaru Okabe, Osaka University, for kindly providing the pCX-EGFP plasmid. We thank Nelson Argumedo Rueda, Hospital Italiano, for help in the preparation of this manuscript.
Author contributions
CG, PA and FPB conceived and designed the experiments. CG, MI and FPB performed the experiments. CG and FPB analyzed the data. AM and LG contributed reagents/materials/analysis tools. CG and FPB wrote the paper. FPB is the guarantor of this work and as such had full access to all of the data in the study and assumes responsibility for the integrity of the data and the accuracy of the data analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Gene Therapy website
Supplementary information
Rights and permissions
About this article
Cite this article
Giménez, C., Ielpi, M., Mutto, A. et al. CRISPR-on system for the activation of the endogenous human INS gene. Gene Ther 23, 543–547 (2016). https://doi.org/10.1038/gt.2016.28
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2016.28
This article is cited by
-
Advances in CRISPR therapeutics
Nature Reviews Nephrology (2023)
-
Current advances and future prospects in production of recombinant insulin and other proteins to treat diabetes mellitus
Biotechnology Letters (2022)
-
From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Progress and Challenges
Stem Cell Reviews and Reports (2020)
-
Delivery systems of CRISPR/Cas9-based cancer gene therapy
Journal of Biological Engineering (2018)
-
CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?
Stem Cell Research & Therapy (2017)